Clinical impact of the Predict Prostate risk communication tool in men newly diagnosed with non-metastatic prostate cancer: a multi-centre randomised controlled trial
David Thurtle, Val Jenkins, Alex Freeman, Mike Pearson, Gabriel Recchia, Priya Tamer, Kelly Leonard, Paul Pharoah, Jonathan Aning, Sanjeev Madaan, Chee Goh, Serena Hilman, Stuart McCracken, Petre Cristian Ilie, Henry Lazarowicz, Vincent Gnanapragasam
doi: https://doi.org/10.1101/2021.01.24.21249948
David Thurtle
1University of Cambridge
Val Jenkins
2SHORE-C, University of Sussex
Alex Freeman
3Winton Centre, University of Cambridge
Mike Pearson
3Winton Centre, University of Cambridge
Gabriel Recchia
3Winton Centre, University of Cambridge
Priya Tamer
4Addenbrooke's Hospital, Cambridge
Kelly Leonard
5Addenbrookes Hospital, Cambridge
Paul Pharoah
1University of Cambridge
Jonathan Aning
6Department of Urology, Bristol Urological Institute, North Bristol NHS Trust
Sanjeev Madaan
7Darent Valley Hospital,
Chee Goh
8Surrey and Sussex Healthcare NHS Trust
Serena Hilman
9University Hospitals Bristol and Weston NHS Foundation Trust
Stuart McCracken
10City Hospitals Sunderland NHS Trust
Petre Cristian Ilie
11Research and Innovation Department, The Queen Elizabeth Hospital, King's Lynn
Henry Lazarowicz
12Royal Liverpool and Broadgreen University Hospitals NHS Trust
Vincent Gnanapragasam
13Department of Surgery, University of Cambridge
Data Availability
Formal requests for access to data should be made to the authors.
Posted January 26, 2021.
Clinical impact of the Predict Prostate risk communication tool in men newly diagnosed with non-metastatic prostate cancer: a multi-centre randomised controlled trial
David Thurtle, Val Jenkins, Alex Freeman, Mike Pearson, Gabriel Recchia, Priya Tamer, Kelly Leonard, Paul Pharoah, Jonathan Aning, Sanjeev Madaan, Chee Goh, Serena Hilman, Stuart McCracken, Petre Cristian Ilie, Henry Lazarowicz, Vincent Gnanapragasam
medRxiv 2021.01.24.21249948; doi: https://doi.org/10.1101/2021.01.24.21249948
Clinical impact of the Predict Prostate risk communication tool in men newly diagnosed with non-metastatic prostate cancer: a multi-centre randomised controlled trial
David Thurtle, Val Jenkins, Alex Freeman, Mike Pearson, Gabriel Recchia, Priya Tamer, Kelly Leonard, Paul Pharoah, Jonathan Aning, Sanjeev Madaan, Chee Goh, Serena Hilman, Stuart McCracken, Petre Cristian Ilie, Henry Lazarowicz, Vincent Gnanapragasam
medRxiv 2021.01.24.21249948; doi: https://doi.org/10.1101/2021.01.24.21249948
Subject Area
Subject Areas
- Addiction Medicine (376)
- Allergy and Immunology (690)
- Anesthesia (185)
- Cardiovascular Medicine (2780)
- Dermatology (237)
- Emergency Medicine (418)
- Epidemiology (12430)
- Forensic Medicine (10)
- Gastroenterology (787)
- Genetic and Genomic Medicine (4297)
- Geriatric Medicine (397)
- Health Economics (705)
- Health Informatics (2776)
- Health Policy (1029)
- Hematology (371)
- HIV/AIDS (882)
- Medical Education (406)
- Medical Ethics (113)
- Nephrology (455)
- Neurology (4072)
- Nursing (218)
- Nutrition (603)
- Oncology (2154)
- Ophthalmology (608)
- Orthopedics (252)
- Otolaryngology (313)
- Pain Medicine (257)
- Palliative Medicine (79)
- Pathology (480)
- Pediatrics (1152)
- Primary Care Research (473)
- Public and Global Health (6677)
- Radiology and Imaging (1457)
- Respiratory Medicine (889)
- Rheumatology (425)
- Sports Medicine (354)
- Surgery (467)
- Toxicology (57)
- Transplantation (194)
- Urology (172)